Abstract:Purpose: To investigate the radiolabeling of E-B5, a monoclonal antibody against Pro-GastrinReleasing Peptide(31-98)by Iodine and study the stability and immunoreactivity of I-E-B5. To determine the in vivo biodistribution of I-E-B5 in normal Kunming mouse and small cell lung cancerbearing nude mouse models(SCLC mouse model) to study the pharmacokinetics of the I-E-B5 in vivo. Characterize the radioimmunoimaging effect and the best imaging time of I-E-B5 in different types of tumors. Methods: I-E-B5 was labeled by chloramine–T method. The labeling efficiency and radiochemical purity were determined by thin-layer chromatography. The I-E-B5 was incubated at 37°C water bath by itself or mixed with normal human serum, the radiochemical purity was then checked at different time points to determine its stability, and the immunoreactivity was determined by cell binding assays.I-E-B5 was injected into the tail veins of the normal Kunming mice which were sacrificed at different time points after injection, and the blood and representative tissues were collected immediately, and the %ID/g (percentage injected dose per gram of tissue) and pharmacokinetic parameters were calculated at various time points. Similarly, T/NT (tumor to non-tumor radioacticity ratio) at various time points were calculated after injection of I-E-B5 into the SCLC model. Mouse models bearing small cell lung cancer, lung adenocarcinoma, colon cancer were utilized to study the radioimmunoimaging effect of I-E-B5, and calculate the T/B ratio (tumor volume to the corresponding location at the other side). Results: I-E-B5 labeling rate was 90.8%, radiochemical purity was 99.28%, and radioactivity was 2.69 MBq/ug. The radiochemical purity of I-E-B5 was 90% after 6 hr at 37°C water bath, and remained at more than 70% after 24 hrs. The radiochemical purity was over 68.1% after 24 hrs mixing with normal human serum. The immunobinding rate of I-E-B5 to NCI-H446 (SCLC cell lines) and A549 (lung adenocarcinoma cell lines) was 71.6%, and 33.2%, respectively. The pharmacokinetics of I-E-B5 is consistent with a two-compartment model with first-order absorption. It was primarily metabolized via liver and kidney. The serum clearance rate is relatively fast. The %ID/g of I-E-B5 in xenografts was dramatically increased to a level much higher than other tissues 48 hrs after injection, reached plateau at 72 hr, and the T/NT ratio was also gradually increased with time. Prominent uptake of I-E-B5 in xenografts of SCLC in nude mice was observed after 24 hrs of injection. The radioactivity in the xenografts was gradually increased with time, and reached the peak at 72 and 96 hr. Xenografts of colon cancer showed similar results as that of SCLC although at a lower level. No observable accumulation was seen in the xenografts of lung adenocarcinoma. The T/B ratio in xenografts of SCLC was consistently higher than in colon cancer at all the time points, and both were significantly higher than that of lung adenocarcinoma which remained stable during the observation duration. Conclusion: The labeling rate and radiochemical purity of I-E-B5 were high and stable both in vivo and vitro. The labeled E-B5 kept its immunologic activity. I-E-B5 selectively accumulated at tumors expressing proGRP, and could effectively target SCLC, therefore is a promising radioimmunoimaging reagent for SCLC.

Pharmacokinetics and Tissue Distribution of 131I-labeled Emodin Following Intravenous Administration to Animals

Pharmacokinetics and Tissue Distribution of Emodin Loaded Nanoemulsion in Rats

Biodistribution of 188Re-Aedp in Rats and Its Dependenceon Rhenium Carrier

Study on Tissue Distribution of Emodin Solid Lipid Nanoparticles in Mice

Study on Pharmacokinetics of Emodin Solid Lipid Nanoparticles in Rats

The Pharmacokinetics of ~(125)I-R-sak in Rats

Study on Body Distribution and Hepatic Targeting Tendency of Galactosyl Adriamycin Bovine Serum Albumin Nanoparticles in Mice by Radioisotope Tracing

Validation study of 131I-RRL: Assessment of biodistribution, SPECT imaging and radiation dosimetry in mice

Study on biodistribution of ~(131)iodine labeled monoclonal antibody D-D_3 against pro-gastrin-releasing peptide_((31-98)) in healthy Kunming mice

Quantitation assay for absorption and first-pass metabolism of emodin in isolated rat small intestine using liquid chromatography-tandem mass spectrometry.

Radiolabeling Morpholino Oligonucleotide with 111in and Its Biodistribution in Normal Mice

Radioiodinated of Gambogic Acid and Its Biodistribution in Mice

Labeling of Annexin V With ~(125)I and Its Biodistribution in Mice

Therapeutic Effect and Anti-Free Radical Injury of Emodin on Acute Radiation Enteritis

^125I-Interleukin-8 Radiolabelling and in Vivo Distribution

The Labeling of [Tyr~3]-Octreotide with ~(125)I and Its Biodistribution and Pharmacokinetic

~(125)I/~(111)in Labeled Anti-EGFR Monoclonal Antibody Panitumumab:Preparation and Biodistribution Evaluation in Normal Mice

The Research on Biodistribution of ~(131)I-Iodosennoside A in Normal Mice and to Evaluate Myocardial Activity

Study on Biodistribution and Radioimmunoimaging of (131)Iodine-Labeled Monoclonal Antibody D-D3 Against Progastrin-Releasing Peptide((31-98)) in Tumor-Bearing Mouse

Experimental study of pharmacokinetics and radioimmunoimaging of 131 Iodine-labeled monoclonal antibody E-B 5 against Pro-Gastrin-Releasing Peptide ( 31-98 )

Comprehensive spatial distribution profiling of bioactive emodin in mouse organs using mass spectrometry imaging